Arca
Skip to content
Tools
Tools

Label Changes: Rozlytrek (entrectinib)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Rozlytrek label DailyMed has published, from Genentech, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 15
  • Sections changed, version 18 to 19: 12

What changed from version 18 to version 19

Dec 10, 2025 to Oct 16, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Dosage and administrationChanged · 138 words added, 122 removed
  2. Warnings and precautionsChanged · 260 words added, 200 removed
  3. Adverse reactionsChanged · 82 words added, 26 removed
  4. Drug interactionsChanged · 17 words added, 8 removed
  5. Use in specific populationsChanged · 1 word added
  6. DescriptionChanged · punctuation or symbols only
  7. Clinical pharmacologyChanged · 41 words added, 11 removed
  8. Patient counseling informationChanged · 56 words added, 39 removed
  9. Patient informationChanged · 283 words added, 270 removed
  10. PRINCIPAL DISPLAY PANEL - 100 mg Capsules Bottle CartonChanged · 1 word added, 1 removed
  11. PRINCIPAL DISPLAY PANEL - 200 mg Capsules Bottle CartonChanged · 1 word added, 1 removed
  12. Untitled sectionChanged · 1 word added, 1 removed

Dosage and administration

Changed138 words added, 122 removed
5 unchanged lines
Before initiating ROZLYTREK, evaluate:
leftLeft ventricular ejection fraction (LVEF) [see Warnings and Precautions (5.1)]
serum uric acid levels [see Warnings and Precautions (5.5)]
QRS and QTc intervals and electrolytes [see Warnings and Precautions (5.2)]
QTSerum intervaluric andacid electrolyteslevels [see Warnings and Precautions (5.6)]
2.3 ROZLYTREK Dosage Form Overview
3 unchanged lines
Whole capsules: For patients who can swallow whole capsules and whose doses are multiples of 100 mg.
Capsules prepared as an oral suspension: For patients who have difficulty or are unable to swallow capsules or who require enteral administration (e.g., gastric or nasogastric tube). [see Dosage and Administration (2.79)]. For dose increments of 10 mg, only use capsules prepared as a suspension.
ROZLYTREK Oral Pellets 50 mg per packet
2 unchanged lines
Administer ROZLYTREK capsules, capsules prepared as a suspension, or pellets once daily, with or without food.
If a dose of ROZYTREKROZLYTREK is missed, make up that dose unless the next dose is due within 12 hours.
If vomiting occurs immediately after taking a dose of ROZLYTREK, repeat that dose.
32 unchanged lines
Grade 4 | Permanently discontinue ROZLYTREK.
Central Nervous System Effects [see Warnings and Precautions (5.2)] | Intolerable Grade 2 | Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline. Resume at same dose or reduced dose, as clinically appropriate.
QRS or QTc Interval Prolongation [see Warnings and Precautions (5.2)] | QRS > 120 ms OR QTc > 500 ms | Withhold ROZLYTREK until QRS or QTc interval recovers to baseline. Resume at same dose if factors that caused QRS or QTc prolongation are identified and corrected. Resume at reduced dose if other factors that cause QRS or QTc prolongation have not been identified.
Ventricular tachycardia (Grade 3 or 4); signs/symptoms of serious arrhythmia; or Brugada syndrome | Permanently discontinue ROZLYTREK.
Central Nervous System Effects [see Warnings and Precautions (5.3)] | Intolerable Grade 2 | Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline. Resume at same dose or reduced dose, as clinically appropriate.
Grade 3 | Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline. Resume at reduced dose.
Grade 4 | Permanently discontinue ROZLYTREK.
Hepatotoxicity [see Warnings and Precautions (5.45)] | Grade 3 | Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline. Resume at same dose if resolution occurs within 4 weeks. Permanently discontinue if adverse reaction does not resolve within 4 weeks. Resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks.
Grade 4 | Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline. Resume at reduced dose if resolution occurs within 4 weeks. Permanently discontinue if adverse reaction does not resolve within 4 weeks. Permanently discontinue for recurrent Grade 4 events.
ALT or AST greater than 3 times ULN with concurrent total bilirubin greater than 1.5 times ULN (in the absence of cholestasis or hemolysis). | Permanently discontinue ROZLYTREK.
Hyperuricemia [see Warnings and Precautions (5.56)] | Symptomatic or Grade 4 | Initiate urate-lowering medication. Withhold ROZLYTREK until improvement of signs or symptoms. Resume ROZLYTREK at same or reduced dose.
QT Interval Prolongation [see Warnings and Precautions (5.6)] | QTc greater than 500 ms | Withhold ROZLYTREK until QTc interval recovers to baseline. Resume at same dose if factors that cause QT prolongation are identified and corrected. Resume at reduced dose if other factors that cause QT prolongation are not identified.
Torsade de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia | Permanently discontinue ROZLYTREK.
Vision Disorders [see Warnings and Precautions (5.7)] | Grade 2 or above | Withhold ROZLYTREK until improvement or stabilization. Resume at same dose or reduced dose, as clinically appropriate.
5 unchanged lines
Avoid coadministration of ROZLYTREK with moderate or strong CYP3A inhibitors. If coadministration cannot be avoided, reduce the ROZLYTREK dose as shown in Table 5 and limit coadministration to 14 days or less.
Table 5. Recommended Dose Modifications of ROZYLTREKROZLYTREK for Concomitant Use with Moderate or Strong CYP3A Inhibitors for Adults and Pediatric Patients 2 Years and Older
Starting dose | Moderate CYP3A inhibitor | Strong CYP3A inhibitor
43 unchanged lines

Warnings and precautions

Changed260 words added, 200 removed
3 unchanged lines
Assess left ventricular ejection fraction (LVEF) prior to initiation of ROZLYTREK. Monitor patients for clinical signs and symptoms of CHF, including shortness of breath and edema. For patients with myocarditis, with or without a decreased ejection fraction, MRI or cardiac biopsy may be required to make the diagnosis. For patients with new onset or worsening CHF, withhold ROZLYTREK, institute appropriate medical management, and reassess LVEF. Based on the severity of CHF or worsening LVEF, resume ROZLYTREK at a reduced dose upon recovery to baseline or permanently discontinue [see Dosage and Administration (2.7)].
5.2 Ventricular Arrhythmias
Among the 355 patients who received ROZLYTREK across the clinical trials, 3.1% of patients with at least one post-baseline ECG assessment experienced QTc interval prolongation of > 60 ms after starting ROZLYTREK and 0.6% had a QTc interval > 500 ms.
Monitor patients who have or are at significant risk of developing QTc interval prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QTc prolongation. Assess QTc interval and electrolytes prior to initiation of ROZLYTREK and periodically during treatment, adjusting frequency based upon risk factors such as congestive heart failure, electrolyte abnormalities, or concomitant medications known to prolong the QTc interval.
Brugada pattern, Brugada syndrome, and ventricular tachycardia have been reported in the postmarketing setting in patients who received ROZLYTREK [see Adverse Reactions (6.2)]. Monitor patients who have or are at significant risk of developing QRS prolongation, including patients with known Brugada syndrome, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QRS prolongation [see Drug Interactions (7.2), Clinical Pharmacology (12.2)].
Based on the severity of QRS or QTc interval prolongation, withhold ROZLYTREK and then resume at same or reduced dose, or permanently discontinue [see Dosage and Administration (2.7)].
5.23 Central Nervous System Effects
A broad spectrum of central nervous system (CNS) adverse reactions occurred in patients receiving ROZLYTREK, including cognitive impairment, mood disorders, dizziness, and sleep disturbances.
Among the 355 patients who received ROZLYTREK across clinical trials, 96 (27%) experienced cognitive impairment; symptoms occurred within 3 months of starting ROZLYTREK in 74 (77%). Cognitive impairment included cognitive disorders (8%), confusional state (7%), disturbance in attention (4.8%), memory impairment (3.7%), amnesia (2.5%), aphasia (2.3%), mental status changes (2%), hallucinations (1.1%), and delirium (0.8%). Grade 3 cognitive adverse reactions occurred in 4.5% of patients. Among the 96 patients with cognitive impairment, 13% required a dose reduction, 18% required dose interruption and 1% discontinued ROZLYTREK due to cognitive adverse reactions.
Grade 3 cognitive adverse reactions occurred in 4.5% of patients. Among the 96 patients with cognitive impairment, 13% required a dose reduction, 18% required dose interruption and 1% discontinued ROZLYTREK due to cognitive adverse reactions.
Among the 355 patients who received ROZLYTREK across clinical trials, 36 (10%) experienced mood disorders. The median time to onset of mood disorders was 1 month (range: 1 day to 9 months). Mood disorders occurring in ≥ 1% of patients included anxiety (4.8%), depression (2.8%) and agitation (2%). Grade 3 mood disorders occurred in 0.6% of patients. One completed suicide was reported 11 days after treatment had ended. Among the 36 patients who experienced mood disorders, 6% required a dose reduction, 6% required dose interruption and no patients discontinued ROZLYTREK due to mood disorders.
3 unchanged lines
Advise patients and caregivers of these risks with ROZLYTREK. Advise patients not to drive or operate hazardous machinery if they are experiencing CNS adverse reactions. Withhold and then resume at same or reduced dose upon improvement, or permanently discontinue ROZLYTREK based on severity [see Dosage and Administration (2.7)].
5.34 Skeletal Fractures
ROZLYTREK increases the risk of fractures. In an expanded safety population that included 338 adult patients and 76 pediatric patients who received ROZLYTREK across clinical trials, 5% of adult patients and 25% of pediatric patients experienced fractures [see Use in Specific Population (8.4)]. In adult and pediatric patients, some fractures occurred in the setting of a fall or other trauma to the affected area; in pediatric patients some fractures occurred with no trauma. In general, there was inadequate assessment for tumor involvement at the site of fracture; however, radiologic abnormalities possibly indicative of tumor involvement were reported in some adult patients. In both adult and pediatric patients, most fractures were hip or other lower extremity fractures (e.g., femoral or tibial shaft). In two pediatric patients, bilateral femoral neck fractures occurred. A total of 41 fracture events were reported in 19 pediatric patients, with 13 patients who experienced more than one occurrence of fracture. Among the 19 pediatric patients who experienced fractures, 17 patients were less than 12 years of age. Among the 41 fracture events, 27 fracture events resolved, 4 fracture events resolved with sequelae and 3 events were resolving. The median time to fracture was 3.8 months (range 0.3 to 18.5 months) in adults and 4.3 months (range: 2 months to 28.7 months) in pediatric patients. ROZLYTREK was interrupted in 41% of adults and 16% of pediatric patients who experienced fractures. Five pediatric patients discontinued treatment due to fractures.
Promptly evaluate patients with signs or symptoms (e.g., pain, changes in mobility, deformity) of fractures. There are no data on the effects of ROZLYTREK on healing of known fractures and risk of future fractures.
5.45 Hepatotoxicity
Among the 355 patients who received ROZLYTREK, increased AST of any grade occurred in 42% of patients and increased ALT of any grade occurred in 36%. Grade 3 – 4 increased AST or ALT occurred in 2.5% and 2.8% of patients, respectively; the incidence may be underestimated as 4.5% of patients had no post-treatment liver function tests [see Adverse Reactions (6.1)]. The median time to onset of increased AST was 2 weeks (range: 1 day to 29.5 months). The median time to onset of increased ALT was 2 weeks (range: 1 day to 9.2 months). Increased AST or ALT leading to dose interruptions or reductions occurred in 0.8% and 0.8% of patients, respectively. ROZLYTREK was discontinued due to increased AST or ALT in 0.8% patients.
Monitor liver tests, including ALT and AST, every 2 weeks during the first month of treatment, then monthly thereafter, and as clinically indicated. Withhold or permanently discontinue ROZLYTREK based on the severity. If withheld, resume ROZLYTREK at the same or reduced dose [see Dosage and Administration (2.7)].
5.56 Hyperuricemia
Among 355 patients who received ROZLYTREK across clinical trials, 32 patients (9%) experienced hyperuricemia reported as adverse reactions with symptoms, as well as elevated uric acid levels. Grade 4 hyperuricemia occurred in 1.7% of patients, including one patient who died due to tumor lysis syndrome. Among the 32 patients with hyperuricemic adverse reactions, 34% required urate-lowering medication to reduce uric acid levels, 6% required dose reduction and 6% required dose interruption. Hyperuricemia resolved in 73% of patients following initiation of urate-lowering medication without interruption or dose reduction of ROZLYTREK. No patients discontinued ROZLYTREK due to hyperuricemia.
Assess serum uric acid levels prior to initiation of ROZLYTREK and periodically during treatment. Monitor patients for signs and symptoms of hyperuricemia. Initiate treatment with urate-lowering medications as clinically indicated and withhold ROZLYTREK for signs and symptoms of hyperuricemia. Resume ROZLYTREK at same or reduced dose upon improvement of signs or symptoms based on severity [see Dosage and Administration (2.7)].
5.6 QT Interval Prolongation
Among the 355 patients who received ROZLYTREK across the clinical trials, 3.1% of patients with at least one post-baseline ECG assessment experienced QTcF interval prolongation of > 60 ms after starting ROZLYTREK and 0.6% had a QTcF interval > 500 ms [see Adverse Reactions (6.1), Clinical Pharmacology (12.2)].
Monitor patients who already have or who are at significant risk of developing QTc interval prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Assess QT interval and electrolytes prior to initiation of ROZLYTREK and periodically during treatment, adjusting frequency based upon risk factors such as congestive heart failure, electrolyte abnormalities, or concomitant medications known to prolong the QTc interval. Based on the severity of QTc interval prolongation, withhold ROZLYTREK and then resume at same or reduced dose, or permanently discontinue [see Dosage and Administration (2.7)].
5.7 Vision Disorders
5 unchanged lines

Adverse reactions

Changed82 words added, 26 removed
2 unchanged lines
Congestive Heart Failure [see Warnings and Precautions (5.1)]
Central Nervous System Effects [see Warnings and Precautions (5.2)]
Ventricular Arrhythmias [see Warnings and Precautions (5.2)]
Skeletal Fractures [see Warnings and Precautions (5.3)]
Central Nervous System Effects [see Warnings and Precautions (5.3)]
HepatotoxicitySkeletal Fractures [see Warnings and Precautions (5.4)]
HyperuricemiaHepatotoxicity [see Warnings and Precautions (5.5)]
QT Interval ProlongationHyperuricemia [see Warnings and Precautions (5.6)]
Vision Disorders [see Warnings and Precautions (5.7)]
54 unchanged lines
Rash | 11 | 0.8
Clinically relevant adverse reactions occurring in ≤ 10% of patients include dysphagia (10%), fall (8%), pleural effusion (8%), fractures (6%), hypoxia (4.2%), pulmonary embolism (3.9%), syncope (3.9%), congestive heart failure (3.4%), and QTQTc prolongation (3.1%).
Table 8 summarizes the laboratory abnormalities.
22 unchanged lines
Safety in Pediatric Patients
The safety of ROZLYTREK was evaluated was evaluated in pediatric patients with unresectable or metastatic solid tumors with a NTRK gene fusion enrolled in one of three multicenter, open-label clinical trials: STARTRK-NG (n=68), TAPISTRY (n=6) and STARTRK-2 (n=2). Patients received ROZLYTREK 20 mg to 600 mg based on body surface area (BSA) orally or via enteral feeding tube once daily in 4-week cycles until unacceptable toxicity or disease progression. Among patients who received ROZLYTREK, 58% were exposed for 6 months or longer and 38% were exposed for greater than one year.
The median age of patients who received ROZLYTREK was 6 years (range: 0 to 17); 51% were females; 68% were White, 18% Asian, 7% Black or African American, and 7% were other races.
55 unchanged lines
Other clinically relevant laboratory abnormalities in patients who received ROZLYTREK included decreased phosphorous.
6.2 Postmarketing Experience
The following adverse reactions have been identified during post-approval use of ROZLYTREK. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiac Disorders: Brugada pattern and Brugada syndrome, including documented monomorphic ventricular tachycardia.

Drug interactions

Changed17 words added, 8 removed
9 unchanged lines
Coadministration of ROZLYTREK with a strong or moderate CYP3A inducer decreases entrectinib plasma concentrations [see Clinical Pharmacology (12.3)], which may reduce ROZLYTREK efficacy. Avoid coadministration of strong and moderate CYP3A inducers with ROZLYTREK.
7.2 Drugs That Prolong QRS or QTc Interval
QRS prolongation, including Brugada pattern or syndrome, and QTc interval prolongation can occur with ROZLYTREK. Avoid coadministration of ROZLYTREK with other products withthat acan knownprolong potentialthe toQRS prolongor QT/QTc interval [see Warnings and Precautions (5.62), Clinical Pharmacology (12.2)].

Use in specific populations

Changed1 word added
22 unchanged lines
8.4 Pediatric Use
The safety and effectiveness of ROZLYTREK have been established in pediatric patients older than 1 month of age [see Clinical Studies (14.2)]. Use of ROZLYTREK in these age groups is supported by evidence from adequate and well-controlled studies of ROZLYTREK in adults and pediatric patients with additional population pharmacokinetic data demonstrating that the exposure of drug substance in pediatric patients greater than 1 month of age is expected to be in the adult range, and that the course of disease is sufficiently similar in adult and pediatric patients to allow extrapolation of data in adults to pediatric patients.
The safety and effectiveness of ROZLYTREK have not been established in pediatric patients with ROS1-positive NSCLC.
11 unchanged lines

Description

Changedpunctuation or symbols only
2 unchanged lines
Entrectinib is white to pale pink powder.
Capsules:
ROZLYTREK (entrectinib) capsules for oral use are supplied as printed hard-shell capsules containing 100 mg (yellow opaque HPMC capsule) or 200 mg of entrectinib (orange opaque HPMC capsule). Inactive ingredients are tartaric acid, lactose anhydrous, hypromellose, crospovidone, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
The yellow opaque capsule shell contains hypromellose, titanium dioxide, and yellow iron oxide. The orange opaque capsule shell contains hypromellose, titanium dioxide, and FD&C yellow #6. The printing ink contains shellac, propylene glycol, strong ammonia solution, and FD&C blue #2 aluminum lake.
Pellets:
ROZLYTREK (entrectinib) oral pellets are supplied as brownish orange or grayish orange, round film-coated pellets in packets. Each packet contains 50 mg of entrectinib and the following inactive ingredients: tartaric acid, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, sodium stearyl fumarate, mannitol, and magnesium stearate.
1 unchanged line

Clinical pharmacology

Changed41 words added, 11 removed
7 unchanged lines
Cardiac Electrophysiology
Across clinical trials, 3.1% of 355 patients, who received ROZLYTREK at doses ranging from 100 mg to 2600 mg daily under fasting or fed conditions (75% received 600 mg orally once daily) and had at least one post-baselinepostbaseline ECG assessment, experienced QTcF interval prolongation of > 60 ms after starting ROZLYTREK and 0.6% had a QTc interval > 500 ms [see Warnings and Precautions (5.62)].
At the maximum recommended ROZYLTREK dosage of 600 mg once daily, a small increase in mean QRS was observed [see Warnings and Precautions (5.2)].
12.3 Pharmacokinetics
2 unchanged lines
Parameter | Entrectinib Mean (% CV) | M5 Mean (% CV)
AUCD1 (nM*h) | 3180031,800 (48%) | 1020010,200 (82%)
AUCss (nM*h) | 4800048,000 (77%) | 2400024,000 (97%)
CmaxD1 (nM) | 22502,250 (58%) | 622 (79%)
Cmaxss (nM) | 31303,130 (80%) | 12501,250 (90%)
Racc(AUC) | 1.55 (49%) | 2.84 (93%)
7 unchanged lines
Entrectinib and its active major metabolite M5 are both > 99% bound to human plasma proteins in vitro.
The estimated apparent volume of distribution (V/F) was 551 L and 81.1 L for entrectinib and M5, respectively.
Elimination
25 unchanged lines

Patient counseling information

Changed56 words added, 39 removed
3 unchanged lines
Inform patients of the risks of CHF and advise patients to contact their healthcare provider immediately for any new or worsening signs or symptoms of CHF [see Warnings and Precautions (5.1)].
Ventricular Arrhythmias
Inform patients of the risks of QRS or QTc interval prolongation and Brugada syndrome, and advise them to report a history of Brugada syndrome, clinically significant arrhythmias, or heart failure and to contact their healthcare provider immediately for severe dizziness, syncope or palpitations [see Warnings and Precautions (5.2)].
Central Nervous System Effects
Advise patients to inform their healthcare provider if they experience new or worsening central nervous system symptoms. Instruct patients not to drive or operate hazardous machinery if they are experiencing CNS adverse reactions [see Warnings and Precautions (5.23)].
Skeletal Fractures
Inform patients that bone fractures have been reported in patients taking ROZLYTREK. Advise patients to report symptoms such as pain, changes in mobility, or deformity to their healthcare provider [see Warnings and Precautions (5.34)].
Hepatotoxicity
Advise patients that they will need to undergo laboratory tests to monitor liver function and to immediately report symptoms of hepatotoxicity [see Warnings and Precautions (5.45)].
Hyperuricemia
Advise patients to inform their healthcare provider if they experience signs or symptoms associated with hyperuricemia [see Warnings and Precautions (5.56)].
QT Interval Prolongation
Inform patients of the risks of QT interval prolongation and to advise patients to contact their healthcare provider immediately for any symptoms of QT interval prolongation [see Warnings and Precautions (5.6)].
Vision Disorders
13 unchanged lines
Instruct patients if they miss a dose to make up that dose unless the next dose is due within 12 hours.
Instruct patients if they vomit immediately after taking a dose of ROZLYTREK to take a dose as soon as possible [see Dosage and Administration (2.4)].

Patient information

Changed283 words added, 270 removed
1 unchanged line
| | ROZLYTREK® (roz lye' trek) (entrectinib) capsules | | ROZLYTREK® (roz lye' trek) (entrectinib) oral pellets |
This Patient Information has been approved by the U.S. Food and Drug Administration. | Revised 110/20242026
What is the most important information I should know about ROZLYTREK? ROZLYTREK may cause serious side effects, including: Congestive heart failure. ROZLYTREK may cause congestive heart failure or make the congestive heart failure that you already have worse. Your healthcare provider will do tests before your treatment and may do tests during your treatment with ROZLYTREK to check your heart function. Tell your healthcare provider right away if you have any of the following signs and symptoms of congestive heart failure:
| | persistent coughing or wheezing trouble breathing when lying down sudden weight gain | increasing shortness of breath tiredness, weakness, or fatigue swelling in ankles, feet, or legs | |
Central nervous system (CNS) effects. ROZLYTREK may cause dizziness, changes in your mood, or may affect how you think and cause confusion, hallucinations, and problems with concentration, attention, memory, speaking, understanding what your hear or read, and sleep. Tell your healthcare provider right away if you have any of these symptoms. Bone fractures. ROZLYTREK may increase your risk for bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities. Liver problems (hepatotoxicity). Your healthcare provider will do blood tests to check your liver function during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any of the following symptoms of liver problems:
Changes in the electrical activity of your heart called QRS or QTc prolongation. QRS or QTc prolongation can cause irregular heartbeats (arrhythmias) that can be life-threatening. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you get severe dizziness, lightheadedness, feel faint, or feel your heart beating irregularly or fast during your treatment with ROZLYTREK. These may be symptoms related to arrhythmias. Central nervous system (CNS) effects. ROZLYTREK may cause dizziness, changes in your mood, or may affect how you think and cause confusion, hallucinations, and problems with concentration, attention, memory, speaking, understanding what your hear or read, and sleep. Tell your healthcare provider right away if you have any of these symptoms. Bone fractures. ROZLYTREK may increase your risk for bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities. Liver problems (hepatotoxicity). Your healthcare provider will do blood tests to check your liver function during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any of the following symptoms of liver problems:
| | loss of appetite nausea or vomiting pain in your upper right stomach area | | yellowing of your skin or the white part of your eyes dark urine | |
1 unchanged line
| | red, hot, tender, or swollen joints, especially in your big toe pain in your stomach-area or sides | | nausea or vomiting pink or brown urine |
Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with ROZLYTREK. These may be symptoms related to QT prolongation. Vision problems. ROZLYTREK may cause vision problems. Your healthcare provider may stop ROZLYTREK and refer you to an eye specialist if you develop severe vision problems during treatment with ROZLYTREK. Tell your healthcare provider right away if you have any loss of vision or any change in vision, including:
Vision problems. ROZLYTREK may cause vision problems. Your healthcare provider may stop ROZLYTREK and refer you to an eye specialist if you develop severe vision problems during treatment with ROZLYTREK. Tell your healthcare provider right away if you have any loss of vision or any change in vision, including:
| | double vision blurry vision new or increased floaters | | seeing flashes of light light hurting your eyes
1 unchanged line
What is ROZLYTREK? ROZLYTREK is a prescription medicine used to treat: Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene. Adults and children 1 month of age and older with solid tumors (cancer) that: are caused by certain abnormal NTRK genes, and have spread or if surgery to remove their cancer is likely to cause severe complications, and there is no satisfactory alternative treatment option or the cancer grew or spread on other treatment. It is not known if ROZLYTREK is safe and effective in children with ROS1 NSCLC or in children under 1 month of age with NTRK solid tumors.
Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you: have liverheart orproblems, kidneyincluding problemsa havehistory anyof heart problemsfailure, includingBrugada apattern conditionor calledsyndrome, longor QTQRS syndromeor QTc prolongation. have liver or kidney problems have nervous system (neurological) problems have or have had eye or vision problems are pregnant or plan to become pregnant. ROZLYTREK can cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ROZLYTREK. Females who can become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with ROZLYTREK. Use effective birth control (contraception) during treatment with ROZLYTREK and for at least 5 weeks after the last dose. Males with female partners that can become pregnant: Use effective birth control (contraception) during treatment with ROZLYTREK and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ROZLYTREK passes into your breast milk. Do not breastfeed during treatment with ROZLYTREK and for 7 days (1 week) after the last dose of ROZLYTREK. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Taking ROZLYTREK with certain other medicines may affect the amount of ROZLYTREK or other medicine in your blood and may cause side effects or affect the way that ROZLYTREK or the other medicine work. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
How should I take ROZLYTREK? Take ROZLYTREK exactly as your healthcare provider tells you. Do not change your dose or stop taking ROZLYTREK unless your healthcare provider tells you to. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with ROZLYTREK if you develop certain side effects. Take ROZLYTREK 1 time each day with or without food. Your healthcare provider will either prescribe: ROZLYTREK capsules to be swallowed whole or prepared and taken or given as a suspension or ROZLYTREK oral pellets to be sprinkled on 1 or more spoonfuls of soft food before taking. If you miss a dose of ROZLYTREK, take it as soon as you remember. If your next dose is due within 12 hours, skip the missed dose and take your next dose at your regular time. If you vomit right after taking a dose of ROZLYTREK, you may take the dose again. See the detailed Instructions for Use for information on how to give or take a dose of ROZLYTREK capsules or oral pellets. If you are taking whole ROZLYTREK capsules: Swallow whole capsules with drinking water, as directed by your healthcare provider. Do not crush or chew the capsule. If you are taking ROZLYTREK capsules prepared as a suspension: Carefully open the prescribed number of capsules and pour the contents into room temperature drinking water or milk. Your healthcare provider will tell you how much water or milk to use, how much suspension to take or give, and provide you with a measuring device like an oral syringe or measuring cup. Let the suspension sit for 15 minutes before taking. You may need to take less suspension than you prepared depending on your prescribed dose. Drink water after taking the suspension to make sure you have swallowed all the medicine. If you do not take the suspension right away, you can store it for up to 2 hours at room temperature below 86°F (30°C). Throw away (discard) the unused suspension if it is not used within 2 hours of preparation. If you cannot swallow and have a gastric or nasogastric tube, the suspension can be given through the feeding tube. If you are taking ROZLYTREK oral pellets: Sprinkle the prescribed number of packets of pellets on 1 or more spoonfuls of a soft food like applesauce, yogurt, or pudding, and take within 20 minutes of sprinkling the pellets on the soft food. Do not crush or chew the pellets to avoid a bitter taste. Drink water after taking the prescribed dose to make sure you have swallowed all the medicine. Use the whole packet of pellets. Do not use part of the packet to try to prepare a dose. Do not use the pellets to make a suspension. Do not give the pellets through a gastric or nasogastric tube because the pellets may clog the feeding tube.
5 unchanged lines
General information about the safe and effective use of ROZLYTREK. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ROZLYTREK for a condition for which it was not prescribed. Do not give ROZLYTREK to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ROZLYTREK that is written for health professionals.
What are the ingredients in ROZLYTREK? Active ingredient: entrectinib Inactive ingredients: Capsules: tartaric acid, lactose anhydrous, hypromellose, crospovidone, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. Yellow opaque capsule shell: hypromellose, titanium dioxide, and yellow iron oxide Orange opaque capsule shell: hypromellose, titanium dioxide, and FD&C Yellow No. 6 Printing ink: shellac, propylene glycol, strong ammonia solution, and FD&C Blue No. 2 aluminum lake Pellets: tartaric acid, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, sodium stearyl fumarate, mannitol, and magnesium stearate Film-coating: polyvinyl alcohol (partially hydrolyzed), titanium dioxide, polyethylene glycol 3350, talc, yellow iron oxide, red iron oxide, and ferrosoferric oxide Distributed by: Genentech, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990 ROZLYTREK ® is a registered trademark of Genentech, Inc. ©20242026 Genentech, Inc. For more information, go to www.ROZLYTREK.com or call 1-877-436-3683.

PRINCIPAL DISPLAY PANEL - 100 mg Capsules Bottle Carton

Changed1 word added, 1 removed
7 unchanged lines
Genentech
11013439
11042812

PRINCIPAL DISPLAY PANEL - 200 mg Capsules Bottle Carton

Changed1 word added, 1 removed
7 unchanged lines
Genentech
11013451
11042785

Untitled section

Changed1 word added, 1 removed
2 unchanged lines
ROZLYTREK® is a registered trademark of Genentech, Inc.
©20242026 Genentech, Inc. All rights reserved.

Unchanged: Indications and usage, Dosage forms and strengths, Contraindications, Nonclinical toxicology, Clinical studies, How supplied, Instructions for use, PRINCIPAL DISPLAY PANEL - 50 mg Pellets Packet Carton.

Every version

15 versions of set c7c71b0c-2549-4495-86b6-c2807fa54908, newest first.
VersionPublished on DailyMedCompareSPL file
19Oct 16, 2026Shown belowDownload .zip
18Dec 10, 2025With version 15Download .zip
15Nov 25, 2024With version 13Download .zip
13Feb 8, 2024With version 12Download .zip
12Nov 3, 2023With version 11Download .zip
11Sep 13, 2023With version 10Download .zip
10Jun 28, 2023With version 9Download .zip
9Oct 27, 2022With version 8Download .zip
8Jul 27, 2022With version 7Download .zip
7Nov 17, 2021With version 5Download .zip
5Nov 5, 2020With version 4Download .zip
4Sep 16, 2020With version 3Download .zip
3Jun 10, 2020With version 2Download .zip
2Sep 11, 2019With version 1Download .zip
1Aug 29, 2019First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.